Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) Equity Average: 2011-2025

Historic Equity Average for Sunshine Biopharma (SBFM) over the last 8 years, with Sep 2025 value amounting to $24.9 million.

  • Sunshine Biopharma's Equity Average rose 2.79% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.9 million, marking a year-over-year increase of 2.79%. This contributed to the annual value of $22.4 million for FY2024, which is 4.37% up from last year.
  • Sunshine Biopharma's Equity Average amounted to $24.9 million in Q3 2025, which was up 3.09% from $24.2 million recorded in Q2 2025.
  • Sunshine Biopharma's Equity Average's 5-year high stood at $41.1 million during Q3 2022, with a 5-year trough of -$1.0 million in Q3 2021.
  • For the 3-year period, Sunshine Biopharma's Equity Average averaged around $23.1 million, with its median value being $23.1 million (2025).
  • Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 6,544.31% in 2022, then slumped by 45.21% in 2023.
  • Over the past 5 years, Sunshine Biopharma's Equity Average (Quarterly) stood at -$481,135 in 2021, then surged by 6,544.31% to $31.0 million in 2022, then tumbled by 30.38% to $21.6 million in 2023, then rose by 12.44% to $24.3 million in 2024, then increased by 2.79% to $24.9 million in 2025.
  • Its last three reported values are $24.9 million in Q3 2025, $24.2 million for Q2 2025, and $23.1 million during Q1 2025.